Although genetic gain-of-function mutations in STING cause inflammation and immunodeficiency in model systems, it is less well understood whether repeated treatment with STING agonists will provide therapeutic benefit in cancer and other human diseases or if long-term STING agonism might create immunological defects such as those observed in SAVI. The gene discussed is STING1; the disease is cancer.